Prof. Yotsuyanagi and Prof. Kawaoka of the University of Tokyo announcing the phase I clinical trial of iEvac-Z

Prof. Yotsuyanagi and Prof. Kawaoka of the University of Tokyo announcing the phase I clinical trial of iEvac-Z

Professor Hiroshi Yotsuyanagi, Professor Yoshihiro Kawaoka and their colleagues at the Institute of Medical Science, the University of Tokyo announced on April 5 that they will start Phase I clinical trials of the Ebola vaccine "iEvac-Z" at the hospital affiliated with the Institute this month. iEvac-Z is an inactivated vaccine made from mutant Ebola virus that lacks some of its genes. iEvac-Z is an inactivated vaccine produced from a mutant Ebola virus that lacks some of its genes, and is expected to be highly safe. The research team created a mutant virus that lacks the gene that makes VP30, a protein essential for the multiplication of the Ebola virus. Professor Yotsuyanagi said, "We can assume that there are side effects such as serious allergic symptoms that may occur in general, but nothing specific to iEvac-Z has been reported yet. We are planning to use it on people who are at high risk of infection" he explained. (= December 5, 2019, photo credit: Nikkan Kogyo Shimbun / Kyodo News Images)

  • Product Code
  • ILEA000687996
  • Registered date
  • 2019/12/05 00:00:00
  • Credit
  • THE NIKKAN KOGYO SHIMBUN / Kyodo News Images
  • Media source
  • THE NIKKAN KOGYO SHIMBUN
  • Media size
  • 3456 × 2304 pixel
  • Resolution
  • 72 dpi
  • Deployment size
  • 3.48(MB)*
  • Special instruction
  • **The text may be generated by an automatic translation system**

*File size when opened in Photoshop, etc.

Similar Images & Videos
    KM Biologics begins development of vaccine for novel coronavirus

    KM Biologics begins development of vaccine for novel coronavirus

    KM Biologics (Kita Ward, Kumamoto City) has started to develop a vaccine for a new coronavirus infection. At a press conference held on April 25, President Nagasato said, "Our strength lies in the fact that we have skilled technicians and facilities from our days at the Research Institute for Chemotherapy and Serotherapy (KAKETSUKEN). As a member of the Meiji Group, we will do our utmost to expand this business. The new drug will be developed jointly with the National Institute of Infectious Diseases, the Institute of Medical Science of the University of Tokyo, and the National Institute of Biomedical Innovation, Health and Nutrition. The company will consider using its Kikuchi Research Center in Kikuchi City, Kumamoto Prefecture, and its Koshi Plant in Koshi City, Kumamoto Prefecture, which are capable of producing vaccines for 57 million new influenza cases. (Photo taken on May 25, 2020, location unknown, credit: Nikkan Kogyo Shimbun / Kyodo News Images)
      Press conference on the identification of existing drugs in Japan

      Press conference on the identification of existing drugs in Japan

      The photo shows Professor Junichiro Inoue of the Institute of Medical Science, University of Tokyo taking off his mask for explanation. (March 18, 2020, Yasuda Auditorium, University of Tokyo, Bunkyo-ku, Tokyo; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)
        Press conference on the identification of existing drugs in Japan

        Press conference on the identification of existing drugs in Japan

        Photo shows Yuji Yamanashi, Director of the Institute of Medical Science, University of Tokyo, at a press conference. (March 18, 2020, Yasuda Auditorium, The University of Tokyo, Bunkyo-ku, Tokyo; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)
          Press conference on the identification of existing drugs in Japan

          Press conference on the identification of existing drugs in Japan

          Photo shows Professor Junichiro Inoue of the Institute of Medical Science, University of Tokyo, at a press conference. (March 18, 2020, Yasuda Auditorium, The University of Tokyo, Bunkyo-ku, Tokyo; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)
            Press conference on the identification of existing drugs in Japan

            Press conference on the identification of existing drugs in Japan

            Photo shows Professor Junichiro Inoue of the Institute of Medical Science, University of Tokyo, at a press conference. (March 18, 2020, Yasuda Auditorium, The University of Tokyo, Bunkyo-ku, Tokyo; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)
              Press conference on the identification of existing drugs in Japan

              Press conference on the identification of existing drugs in Japan

              Photo shows Yuji Yamanashi, Director of the Institute of Medical Science, University of Tokyo, at a press conference. (March 18, 2020, Yasuda Auditorium, The University of Tokyo, Bunkyo-ku, Tokyo; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)
                Press conference on the identification of existing drugs in Japan

                Press conference on the identification of existing drugs in Japan

                Photo shows Makoto Gogami, President of the University of Tokyo, at a press conference. (March 18, 2020, Yasuda Auditorium, The University of Tokyo, Bunkyo-ku, Tokyo; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)
                  Professor Inoue of University of Tokyo, announce the identification of a new coronavirus drug candidate

                  Professor Inoue of University of Tokyo, announce the identification of a new coronavirus drug candidate

                  Professor Junichiro Inoue and his colleagues at the University of Tokyo's Institute of Medical Science held a press conference on April 18 and announced that they had identified nafamostat. Nafamostat has been used for more than 30 years in Japan, and early clinical trials are expected to be conducted. The clinical research is expected to start by the beginning of April in cooperation with the National Center for Global Health and Medicine and others. When the new corona infects humans, proteins on the surface of the virus and proteins on the surface of human cells bind to each other, causing the outer membrane of the virus to fuse with the membrane of human cells. As a result, ribonucleic acid (RNA), which is the genetic information of the new corona, enters the human cell, and the virus multiplies. (March 18, 2020, Yasuda Auditorium, The University of Tokyo, Bunkyo-ku, Tokyo; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)
                    Press conference on the identification of existing drugs in Japan

                    Press conference on the identification of existing drugs in Japan

                    Photo shows Professor Junichiro Inoue of the Institute of Medical Science, University of Tokyo, wearing a mask at the press conference. (March 18, 2020, Yasuda Auditorium, University of Tokyo, Bunkyo-ku, Tokyo; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)
                      Press conference on the identification of existing drugs in Japan

                      Press conference on the identification of existing drugs in Japan

                      Photo shows Makoto Gogami, President of the University of Tokyo, at a press conference. (March 18, 2020, Yasuda Auditorium, The University of Tokyo, Bunkyo-ku, Tokyo; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)